Vertex Pharmaceuticals Incorporated VRTX announced positive results from a phase II study evaluating its NaV1.8 inhibitor VX-150 in patients suffering from pain caused by small fiber neuropathy. The ...
-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the ...
-VX-150 was generally well tolerated and showed statistically significant relief of acute pain compared to placebo; study included an active reference arm of the opioid pain medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback